Promoter holding
64.27%
SL
Synbiotics Limited - Due diligence report
A 360° intelligence report on Synbiotics: trust score, financial health, credit view, compliance, directors, growth and distress signals - g…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Synbiotics — 360° Intelligence Report
Generated from MCA filings & public records60/100
Trust Score
Moderate
Synbiotics is assessed as Moderate with a Trust Score of 60/100. Synbiotics is an active public limited indian non-government company incorporated in 1960, operating in the Chemicals sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and moderate financial risk profile.
Report generated on 21 Jul 2026 from the latest processed filings. Synbiotics Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
60/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
50/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
55/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
45/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
65/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
60/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 55/100 Moderate
- Negative operating earnings - debt service depends on external support.
- Moderate gearing (D/E 38%).
- Working-capital cover adequate.
Charges position: 6 open (15.65 cr) · 13 satisfied (23.48 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| The Kalupur Commercial Co-Operative Bank Limited | 9 | 48.0 cr |
| Others | 2 | 48.0 cr |
| State Bank Of Saurashtra | 2 | 48.0 cr |
| The Kalupur Commercial Co-Operative Bank Ltd. | 5 | 48.0 cr |
| Kalupur Commercial Co-Operative Bank Limited | 1 | 48.0 cr |
Compliance Score: 50/100 Moderate
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Flagged by authority: EPFO.
- Litigation present in 3 court forum(s).
- 1 active GST registration(s).
Legal cases on record (3)
05
Director Intelligence
Stability score: 45/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| ANURAG MARUTBHAI MEHTA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MAYURKUMAR KISHORCHANDRA SWADIA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MOHAL KARTIKEYA SARABHAI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAJIV MOHJIT DHRU | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 4 directors on the board.
- ANURAG MARUTBHAI MEHTA has DIN status "Deactivated".
- 1 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Asence Pharma Private Limited
Subsidiaries
-
Group entities
1
Capital events
-
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Asence Pharma Private Limited | Holding Company | 74.00% |
| Cosara Diagnostics Private Limited | Joint Ventures | 74.00% |
Key managerial personnel: ANURAG MARUTBHAI MEHTA (Whole-time director) · MOHAL KARTIKEYA SARABHAI (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 65 · Distress 60
Growth signals & trust indicators
Steady revenue growth: +1.42 over 4 year(s).
Asset base grew 2.1x - capacity expansion.
Operating for 65+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
Compliance score is weak (50/100).
6 open charge(s) registered - assets are encumbered.
3 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence56/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 2 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment54/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 6 open charge(s) of 15.65 cr already registered.
- Compliance gaps should be priced into terms.
Investor view60/100
Mixed indicators
Growth quality and scalability through an investor lens.
- 2 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management churn warrants questions.
09
MCA Filings & Events Timeline
Latest 15 events25 Jul 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
22 Dec 2023
Charge satisfied
Others
06 Dec 2023
Charge created
The Kalupur Commercial Co-Operative Bank Limited - 2.00 cr
20 Sep 2023
Director ceased
MOHAL KARTIKEYA SARABHAI
17 Oct 2022
Charge created
The Kalupur Commercial Co-Operative Bank Limited - 1.80 cr
11 Oct 2022
Director appointed
ANURAG MARUTBHAI MEHTA (Whole-time director)
Director ceased
ANURAG MARUTBHAI MEHTA
31 Mar 2022
Charge satisfied
The Kalupur Commercial Co-Operative Bank Limited
Charge satisfied
Others
Charge satisfied
The Kalupur Commercial Co-Operative Bank Ltd.
07 Feb 2022
Director ceased
GULAMMOHIYUDDIN ABDULRAHIM TAMAM
14 Sep 2021
Director ceased
MAYURKUMAR KISHORCHANDRA SWADIA
09 Nov 2020
Director appointed
MAYURKUMAR KISHORCHANDRA SWADIA (Director)
09 Sep 2020
Director ceased
AJOY KUMAR PALIT
10
Key Observations
Auto-generated from the data aboveRevenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Debt-to-equity stands at 38% - manageable leverage.
Net worth is positive.
4 active director(s) / partner(s); review board churn before relying on management continuity.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
| Company | CIN | Location |
|---|---|---|
| Matish Healthcare Private Limited | U74999GJ2020PTC112747 | Vadodara, Gujarat, India |
| Phoenix Biologicals | U24100TN2010PTC076804 | Chennai City Corporation, Tamil Nadu, India |
| Kentreck Laboratories Pvt Ltd | U24231GJ1989PTC012216 | Ahmedabad, Gujarat, India |
| Sreepathi Lab Private Limited | U24239TG2004PTC043403 | Nalgonda, Telangana, India |
| Phoenix Bio Sciences Private Limited | U74990TN2011PTC079806 | Vellore, Tamil Nadu, India |
| Defi Healthcare Private Limited | U85110GJ2003PTC043115 | Ahmedabad, Gujarat, India |
| Oltimo Lubes & Chemicals Private Limited | U36990HR2020PTC089712 | Gurgaon, Haryana, India |
| Carbon Light | U24299UP2021PTC147632 | Ghaziabad, Uttar Pradesh, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Synbiotics before audits and certifications: compliance score 50/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Synbiotics: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 65/100, margin trends, ownership structure and peer set for Synbiotics - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 60/100, distress signals and MSME payment-delay disclosures - know whether Synbiotics pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Synbiotics - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Synbiotics an active company?
Synbiotics has MCA status “Active” with a compliance score of 50/100 (Moderate).
Is Synbiotics financially healthy?
Synbiotics has a Financial Health Score of 55/100 (Moderate) based on its filed financial statements.
Should I do business with Synbiotics?
Its overall Trust Score is 60/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Synbiotics?
The ultimate holding entity is Asence Pharma Private Limited. 4 active director(s) are on record.
Does Synbiotics have loans or charges against its assets?
6 open charge(s) are registered against its assets, and 13 earlier charge(s) stand satisfied.
Is Synbiotics up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 50/100 (Moderate).
Is it risky to lend to Synbiotics?
Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
